Powered by CARB-X: Portfolio expansion announced today!

Picture

​Dear All: CARB-X has today announced funding of 7 more companies, bringing the total funded portfolio to 17 potential new therapies (or preventatives) and 1 novel point-of-care diagnostic (see graphic above). Befitting the international nature of those of you who read my occasional notes (see map just below), there are now funded companies in 6 countries (US, UK, France, Switzerland, Ireland, and India). 

Picture

Above: Locations of recent readers of these newsletters. Darker = more readers
You can read more in the press release (and don’t miss the two interactive & clickable portfolio tables), but I think it is particularly exciting that the 7 new projects include five potential new class antibiotics for Gram-negative bacteria. These will take a long time to mature and only a few will ultimately succeed, but the therapeutic part of the portfolio now contains 10 projects that pursue a novel target and 8 that are potential novel class small molecules.  

All best wishes, –jr

PS: For those of you who miss the broadcast or don’t have a local PBS station, the FRONTLINE episode of Hunting the Nightmare Bacteria will be available for streaming at http://www.pbs.org/wgbh/frontline/ beginning sometime in the next 24h.

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://13.43.35.2/blog.html

Upcoming meetings of interest to the AMR community:

Scroll to Top